Catalent shares rise after Argus upgrades rating on post-COVID strategy

September 06, 2023 01:04 AM AEST | By Investing

Google News:

Catalent shares rise after Argus upgrades rating on post-COVID strategy — Image source: Kalkine Media

Recent News

DaVita Releases Annual Community Care Report, Highlights Achievements...

T‑Mobile’s Hometown Grants Program Delivers Nearly $18M in Lasting Cha...

Tapestry’s Jessie Wasser Included in Trellis’ 30 Under 30 List

Fed keeps rates steady, but sees fewer cuts next year on stagflation c...

Investing.com -- Shares in Catalent Inc (NYSE:CTLT) rose in early U.S. trading on Tuesday after analysts at Argus Research upgraded their rating of the biopharmaceutical firm to buy from hold.

The analysts also set their price target for the group at $62, highlighting an "upbeat outlook" from the business for its 2024 fiscal year that included strong projected growth for its "non-COVID revenue."

Last week, the drug-product manufacturer unveiled a 2024 revenue forecast of between $4.3 billion to $4.5 billion that topped estimates, although its guidance for earnings before interest, taxes, depreciation and amortization missed expectations.

In a separate statement, the New Jersey-based company said it would add four new independent directors to its board and undergo a strategic review as part of an agreement with activist investor Elliott Investment Management. The deal, in effect, gives Elliott some sway over determining Catalent's strategy, including a possible sale of all or parts of the company.

During the pandemic, Catalent was boosted by a windfall filling syringes for large pharma companies, but it has since been plagued by production delays at three of its key facilities.

Chief Executive Officer Alessandro Maselli has said that Catalent now has "the right strategy in place," adding that it plans to play a "major role" in GLP-1 drug production. Catalent currently helps manufacture Novo Nordisk's (NYSE:NVO) popular Wegovy weight-loss injection, which is from the class of GLP-1 receptor agonist drugs.

Citing Catalent's relationship with Novo, the Argus analysts said they see "several positive developments as the company transitions to a post-COVID environment with a focus on developing and commercializing advanced biologics and gene therapies."

This article first appeared in Investing.com

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.